BPC-157 Research

Sikiric P, Seiwerth S, Rucman R, et al.

One of the most comprehensive reviews of BPC-157’s wound healing properties, covering over 25 years of research. The review documents BPC-157’s ability to heal skin wounds, burns, diabetic ulcers, and complex fistulas in animal models through a combination of mechanisms — promoting angiogenesis (new blood vessel growth), stimulating collagen deposition, modulating the nitric oxide system, and accelerating re-epithelialization. A key finding is that BPC-157 appears to work regardless of administration route (oral, topical, or injected) and at the same effective dose range across different injury types — an unusual property that suggests it acts on fundamental repair pathways.

Vasireddi N, Hahamyan H, Salata MJ, et al.

The most current systematic review of BPC-157 specifically for musculoskeletal injuries — covering 36 studies from 1993 to 2024. The review found consistent evidence in animal models for BPC-157 promoting healing of muscle, tendon, ligament, and bone injuries by upregulating growth factors and reducing inflammation. Notably, one human study found 7 out of 12 patients with chronic knee pain reported relief lasting over 6 months after a single BPC-157 knee injection. The authors concluded that while results are promising, risks exist due to unregulated manufacturing and the absence of formal human clinical safety data.

Gwyer D, et al.

A comprehensive literature and patent review summarizing BPC-157’s broad biological activities across tissue types. The review covers its effects on the GI tract, liver, pancreas, heart, and nerves — along with musculoskeletal repair. It addresses the regulatory status directly: BPC-157 was temporarily banned by WADA in 2022 (no longer listed as banned), has not been FDA approved due to the absence of comprehensive human clinical trials, and had a Phase 1 human trial initiated in 2015 that was cancelled before results were submitted. The review calls for more extensive human-oriented studies to establish therapeutic and toxicity profiles.

Sikiric P, et al.

This review examines BPC-157’s effects on the gut-brain axis — the bidirectional communication network between the gastrointestinal tract and the central nervous system. The paper documents BPC-157’s success in treating GI conditions including ulcerative colitis, liver lesions, and gut fistulas, as well as its corresponding effects on the brain — including anxiolytic, antidepressant, and neuroprotective properties in animal models. This study is the basis for BPC-157’s reputation as both a gut-healing peptide and a potential CNS-protective compound — two seemingly unrelated applications that connect through the gut-brain axis.

American College of Gastroenterology Research Group

A 2025 systematic review from gastroenterology specialists examining BPC-157’s potential for GI conditions — including mucosal protection, wound healing, inflammatory bowel disease, and NSAID-induced GI injury. The reviewers concluded that BPC-157 shows promise from preclinical studies for a range of GI pathologies, but that its use remains investigational and should not yet be considered standard evidence-based therapy. The review represents mainstream gastroenterology’s first formal acknowledgment of BPC-157’s potential clinical relevance.